← Back to Search

Fasted Exercise for Type 2 Diabetes (FED Trial)

N/A
Waitlist Available
Led By Normand Boulé, PhD
Research Sponsored by University of Alberta
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up change from the first two to the last two weeks of the 16 week interventions
Awards & highlights

Summary

This trial is studying whether exercising before or after breakfast is better for controlling blood sugar in people with type 2 diabetes. The study will last for several months. It aims to find out if exercising before breakfast can improve blood sugar levels more effectively than exercising after breakfast, without needing to increase the amount of exercise.

Eligible Conditions
  • Type 2 Diabetes

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~change from the first two to the last two weeks of the 16 week interventions
This trial's timeline: 3 weeks for screening, Varies for treatment, and change from the first two to the last two weeks of the 16 week interventions for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Concentration of HbA1c (mmol/mol)
Liver fat (%)
Secondary outcome measures
Aerobic fitness
Body weight (kilograms)
Concentrations of Fasting glucose
+9 more

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Fasted ExerciseExperimental Treatment1 Intervention
Exercise training will be performed in the fasted state (i.e., before breakfast).
Group II: Postprandial ExerciseActive Control1 Intervention
Exercise will be performed in the postprandial period (i.e., after breakfast)
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Fasted Exercise
2019
N/A
~40

Find a Location

Who is running the clinical trial?

University of AlbertaLead Sponsor
901 Previous Clinical Trials
387,530 Total Patients Enrolled
Normand Boulé, PhDPrincipal InvestigatorUniversity of Alberta
~3 spots leftby Sep 2025